PIP and glycogen storage disease VI: According to medical literature, Gross cystic disease fluid protein-15 monoclonalantibody (GCDFP-15) or BRST2 has shown sensibility of 55-76% and specificity of 95-100%for the diagnosis of metastatic breast cancer 6,9,.13